Moderna awaits an August 2026 FDA decision on its mRNA flu vaccine while expanding into oncology, autoimmune disease, and monkeypox. Its COVID-19 vaccine Spikevax remains central amid financial losses and cautious analyst sentiment.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07467707 |
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults |
RECRUITING | PHASE3 |
| NCT06007183 |
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination |
ACTIVE_NOT_RECRUITING | PHASE3 |
